Principal Investigator
Gilberto Lopes
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230307
Clinical Trial Summary
A Phase 1, Open-Label, Dose Escalation And Dose Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Anti Tumor Activity Of Pf-07799933 (Arry-440) As A Single Agent And In Combination Therapy In Participants 16 Years And Older With Advanced Solid Tumors With Braf Alterations
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
+1 (954) 8177628